Work

A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in metastatic hormone sensitive prostate cancer patients with HRR gene mutation: Updated analysis of PROact.

Year: 2025

Type: conference-abstract

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.tps292

Authors: Junlong Zhuang, Shun Zhang, Xuyu Zhang, Xuefeng Qiu, Xi Zheng, Jie Gao, Hongqian Guo

Institutions: Nanjing Drum Tower Hospital, Nanjing University, Nanjing Medical University

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4407700029

Cites:

Cited by:

Related to: 10